Marizyme Stock Price, News & Analysis
Company Description
Marizyme (OTC Link: MRZM) is a publicly traded biotechnology company in the Healthcare sector. The company has a market capitalization of $39.5K.
MRZM stock has declined 100.0% over the past year. Shares last traded at $0.0000.
On a trailing twelve-month basis, Marizyme reported revenue of $646K with net income of -$69.5M and diluted earnings per share of $-1.53. The company operates at a net profit margin of -10767.8%.
This page provides a comprehensive overview of MRZM stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Marizyme (MRZM) stock last traded at $0.0000. Over the past 12 months, the stock has lost 100.0%. At a market capitalization of $39.5K, MRZM is classified as a micro-cap stock with approximately 131.8M shares outstanding.
MRZM Rankings
Latest News
Marizyme has 10 recent news articles. Of the recent coverage, 3 articles coincided with positive price movement and 4 with negative movement. Key topics include fda approval, clinical trial, acquisition. View all MRZM news →
SEC Filings
Marizyme has filed 1 recent SEC filing, including 1 Form 8-K. The most recent filing was submitted on April 17, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all MRZM SEC filings →
Financial Highlights
Marizyme generated $646K in revenue over the trailing twelve months, retaining a 70.9% gross margin, operating income reached -$34.1M (-5278.1% operating margin), and net income was -$69.5M, reflecting a -10767.8% net profit margin. Diluted earnings per share stood at $-1.53. The company generated -$4.7M in operating cash flow. With a current ratio of 0.04, short-term liquidity bears monitoring.
Upcoming Events
Short Interest History
Short interest in Marizyme (MRZM) currently stands at 10 shares, representing 0.0% of the float. Over the past 12 months, short interest has increased by 233.3%. This relatively low short interest suggests limited bearish sentiment. With 1000.0 days to cover, it would take significant time for short sellers to close their positions based on average trading volume.
Days to Cover History
Days to cover for Marizyme (MRZM) currently stands at 1000.0 days. This elevated days-to-cover ratio indicates it would take over two weeks of average trading volume for short sellers to exit their positions, suggesting potential for a short squeeze if positive news emerges. The ratio has shown significant volatility over the period, ranging from 1.0 to 1000.0 days.
MRZM Company Profile & Sector Positioning
Marizyme (MRZM) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing MRZM often look at related companies in the same sector, including Navidea Biopharm (NAVB), Syros Pharmaceut (SYRS), Aridis Pharmaceuticals Inc (ARDS), PaxMedica, Inc. (PXMD), and Tracon Pharmaceu (TCON). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate MRZM's relative position within its industry.